New ways to increase HIV prevention among high-risk adults in drinking venues in Kenya and Uganda
Innovative strategies to promote biomedical HIV prevention uptake and retention among high-risk adults at drinking venues in Kenya and Uganda
This study is all about making it easier for adults who drink heavily and are at high risk for HIV to access important prevention services like PrEP and PEP, by offering HIV testing and health check-ups in places where they hang out, so we can help more people stay healthy and informed.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10873234 on NIH RePORTER |
What this research studies
This research focuses on improving access to HIV prevention services, such as pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), for adults at high risk of HIV, particularly those who consume alcohol heavily. The study aims to engage individuals in drinking venues, which are known hotspots for HIV transmission, by integrating HIV testing with other health screenings. By addressing barriers like stigma and misconceptions about risk, the project seeks to recruit over 2,000 participants and evaluate the effectiveness of this approach in promoting HIV prevention uptake and retention.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who frequent drinking venues and are at high risk for HIV.
Not a fit: Patients who do not consume alcohol or are not at risk for HIV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly increase the number of high-risk individuals who access and adhere to HIV prevention services.
How similar studies have performed: Previous research has shown that integrating health services in community settings can effectively increase access to care, suggesting potential success for this novel approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Chamie, Gabriel — University of California, San Francisco
- Study coordinator: Chamie, Gabriel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.